L'Oréal announced on June 18 that it will acquire a majority stake in Innovist, the Indian house behind Bare Anatomy, Chemist at Play, Sunscoop and Vinci Botanicals.
Reports place the transaction at a valuation of roughly 350 to 450 million dollars, though the company did not disclose terms. The deal includes the right to buy out minority holders such as Amazon and Accel over time.
The founding team stays on as minority shareholders and continues to run operations in partnership with L'Oréal India.
For a global major, building four trusted Indian skincare brands from scratch would take years. Buying them removes the slowest part, which is earning a young shopper's first repeat purchase.
The signal underneath the deal is simpler. India's D2C beauty names are no longer acquisition targets of convenience; they are now priced as the distribution that incumbents cannot build fast enough.